×
About 16,363 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  4,940 results

Factors associated with persistence of early-onset atopic dermatitis up to the age of 1...
https://doi.org/10.1684/ejd.2021.4045
European Journal of Dermatology : EJD; Zhang Z, Li H et. al.

Jul 26th, 2021 - Atopic dermatitis (AD) can remit as age increases. However, long-term follow-up studies evaluating disease evolution and related factors of persistence of early-onset AD are sparse. This study aimed to identify factors associated with the persiste...

Dupilumab: An Opportunity to Unravel In Vivo Actions of IL-4 and IL-13 in Humans.
https://doi.org/10.1016/j.jid.2021.02.007
The Journal of Investigative Dermatology; Roesner LM, Bridgewood C et. al.

Jul 25th, 2021 - The application of biologics in clinical practice allows immunological observations under real-life conditions. In a new article in the Journal of Investigative Dermatology, Bakker et al. (2021) use deep immune cell phenotyping to demonstrate how ...

Determination of nasal carriage and skin colonization, antimicrobial susceptibility and...
https://doi.org/10.1186/s12879-021-06382-3 10.3390/jcm8040444 10.1155/2014/354250 10.1016/J.ALIT.2019.02.006 10.1177/1203475415605498 10.1111/j.1399-3038.2007.00586.x 10.1001/jamadermatol.2017.5440 10.1016/j.tim.2017.11.008 10.1016/S1473-3099(05)70295-4 10.1111/j.1365-2133.2007.08197.x 10.1111/j.1523-1755.2005.00174.x 10.3389/fmicb.2018.02419 10.1177/1721727X1301100110 10.1007/s10096-010-1136-3 10.1128/jcm.33.9.2233-2239.1995 10.1016/j.anai.2018.12.003 10.1016/S0091-6749(99)70536-1 10.1016/j.det.2017.02.002 10.1038/nature25177 10.1128/IAI.00958-10 10.1067/mai.2000.105528 10.1111/j.1365-2133.2006.07410.x 10.1155/2018/1956403 10.1016/j.anai.2020.08.002 10.1080/09540105.2020.1747406 10.1080/09540105.2016.1228838 10.1016/j.jid.2018.03.1517 10.2340/00015555-2667 10.1093/jac/dkp159 10.1371/journal.pmed.0050017 10.1046/j.1365-2133.2002.04872.x 10.1111/j.1346-8138.1995.tb03366.x 10.1111/j.1399-3038.2004.00182.x 10.1155/2011/718708 10.1016/0195-6701(95)90079-9 10.1136/bmj.2.4893.912 10.1128/JCM.01734-07 10.3947/ic.2017.49.2.158 10.4103/1319-1683.74320 10.1111/j.1365-2133.2008.08817.x 10.1111/j.1600-0625.2008.00734.x 10.1111/j.1365-2133.2009.09038.x 10.1111/j.1442-200X.2010.03227.x 10.1016/j.jaip.2014.04.007 10.1007/s12088-012-0296-5 10.1086/324626 10.12659/msm.881386 10.1155/1998/538090 10.1111/bjd.18643 10.1177/030006059101900602 10.1111/j.1600-065X.2011.01027.x 10.1542/peds.2008-2217 10.1016/j.jgar.2019.07.032 10.1159/000331910 10.1371/journal.ppat.1008733 10.1007/82_2016_32
BMC Infectious Diseases; Masiuk H, Wcisłek A et. al.

Jul 23rd, 2021 - Atopic dermatitis (AD) is one of the most frequent chronic and inflammatory skin condition. AD is characterized by damaged epidermal barrier, xerosis and pruritus of eczematous skin lesions which tend to flare. The duration and frequency of exacer...

Nuclear IL-33 plays an important role in IL-31-mediated downregulation of filaggrin, ke...
https://doi.org/10.1016/j.jid.2021.05.033
The Journal of Investigative Dermatology; Dai X, Shiraishi K et. al.

Jul 22nd, 2021 - Interleukin (IL)-33, a chromatin-associated multifunctional cytokine, is implicated in the pathogenesis of atopic dermatitis (AD), an inflammatory skin disorder characterized by skin barrier dysfunction. IL-33 accumulates in the nuclei of epiderma...

DNA methylation array identifies golli-MBP as a biomarker for the disease severity in c...
https://doi.org/10.1016/j.jid.2021.06.025
The Journal of Investigative Dermatology; Chen KD, Huang YH et. al.

Jul 22nd, 2021 - In this study, we investigated the changes in the global methylation status and its functional relevance in childhood atopic dermatitis (AD). Differences in epigenome-scale methylation events in peripheral blood associated with childhood AD were s...

see more →

Guidelines  8 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 4th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 5th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 24th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 20th, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 4th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  444 results see all →

Clinicaltrials.gov  308 results

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03703102

May 6th, 2020 - A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically in...

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
https://clinicaltrials.gov/ct2/show/NCT03661866

Apr 27th, 2020 - TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a res...

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT03359356

Apr 23rd, 2020 - The purpose of this study is to assess whether dupilumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 54 subjects with moderate to severe alopecia areata involving...

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
https://clinicaltrials.gov/ct2/show/NCT03720470

Apr 21st, 2020 - B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once dai...

Eucrisa for Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03250663

Apr 20th, 2020 - Atopic Dermatitis (AD) affects between 10% and 30% of all children, making it one of the most common childhood diseases. Recent epidemiological studies report a trend toward the increasing prevalence of AD in children. Symptoms of AD include dry, ...

see more →

News  828 results

Proposed Classification Framework for Atopic Dermatitis Unveiled
https://www.medscape.com/viewarticle/954902

Jul 15th, 2021 - The heterogeneous clinical course of atopic dermatitis (AD) and its differing signs, symptoms, burden, and response to treatment can pose a quandary for physicians. Dr Jonathan Silverberg This is behind a new classification framework called DESCRI...

Dupilumab Safe, Effective in Kids 6-11 With Moderate-to-Severe Asthma
https://www.medscape.com/viewarticle/954586

Jul 9th, 2021 - Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial. A fully human monoclonal antibody, dupilumab also improved lung ...

Study Provides Insights Into Pediatric Psoriasis Over Two Decades
https://www.medscape.com/viewarticle/954411

Jul 7th, 2021 - Obesity, atopic dermatitis, psychiatric disease, and arthritis are the most common comorbidities among infants, children, and adolescents with psoriasis, while predictors of moderate to severe disease include morphology, non-White race, and cultur...

Expert Shares Practical Considerations for Dupilumab Treatment
https://www.medscape.com/viewarticle/954120

Jun 30th, 2021 - Clinicians who struggle to get dupilumab approved for their patients with moderate to severe atopic dermatitis (AD) are not alone. This scenario was illustrated in a 2020 retrospective study of 179 adults with AD who were cared for at the Universi...

Baricitinib Found Effective for Moderate to Severe AD Out to 52 Weeks
https://www.medscape.com/viewarticle/953944

Jun 28th, 2021 - Baricitinib, at a dose of 2 mg a day, demonstrated efficacy in adults with moderate to severe atopic dermatitis up to 52 weeks, integrated data from two trials demonstrated. "With long-term therapy, the baricitinib 2 mg response remains stable or ...

see more →

Patient Education  17 results see all →